Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sonrotoclax + cladribine + cytarabine
- Development stage
- Phase 2
- Lead developer
- BeOne Medicines
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Sonrotoclax + cladribine + cytarabine is an investigational combination therapy being evaluated as a salvage chemotherapy regimen for adult patients with relapsed or refractory acute myeloid leukemia (R/R AML). The regimen consists of **sonrotoclax** (BGB-11417), a highly potent and selective B-cell lymphoma 2 (BCL-2) inhibitor developed by BeiGene; **cladribine**, a purine nucleoside analogue that also downregulates the anti-apoptotic protein MCL-1; and **cytarabine**, a standard antimetabolite that inhibits DNA synthesis. This triplet combination is designed to overcome resistance mechanisms in AML by simultaneously targeting BCL-2 and MCL-1 pathways while inducing DNA damage. In clinical trials, this regimen is being studied as a bridge therapy to achieve remission prior to allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Other names
- Sonrotoclax, Cladribine, and Cytarabine
02
Targets
BCL2L1 (B-cell lymphoma-extra large protein)ABCG2 (Breast cancer resistance protein)DNADNA polymerase familyRNR (Ribonucleotide reductase)MCL1 (Myeloid cell leukemia sequence 1)
Beyond the preview
Go deeper on sonrotoclax + cladribine + cytarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sonrotoclax + cladribine + cytarabine.